Board of Directors
Gisela Sitbon, Ph.D. - Chair of the Board
Board member since 2009, Chair since 2010
Dr Gisela Sitbon (1958), Deputy Region Director at Innovationsbron AB, has more than 25 years of life-science industry experience within the areas of strategic planning, business development, pharmaceutical R&D and quality assurance. She is a non-executive member of the board at a number of companies and organisations including Industrifonden, an independent ever-green fund investing in Swedish growth companies. Through her own company, ZENZ Bioscience Partner AB, Gisela provides consultancy in the areas of business focusing and business development to high-growth companies.
Gisela Sitbon worked for nearly ten years at Professional Genetics Laboratory AB in a number of senior rôles including Managing Director, Vice President Business Development and Head of Research & Development. Prior, she spent five years in several rôles including Section Head and Project Director at Karo Bio AB, a Swedish drug discovery and development company specializing in targeting nuclear receptors. Gisela gained her Doctorate of Medical Sciences from the Karolinska Institute in 1987.
Uli Hacksell, Ph.D.
Board member since 2017
Dr Uli Hacksell (1950) has over 20 years of international management experience from both large pharmaceutical and biotech companies. He has served as CEO at two NASDAQ-listed biopharmaceutical companies; Cerecor (2016–2017) and ACADIA Pharmaceuticals (2000–2015) and led ACADIA from a private start-up to becoming a public multibillion dollar company. Previously, he held senior executive positions at Astra AB (1991–1999) and was president of Astra Draco, one of Astra’s largest R&D subsidiaries.
Uli has a diverse Board experience from several long-term assignments, including SynAct Pharma A/S, SLS Invest AB, Action Pharma A/S and the Swedish Medical Products Agency. He currently serves as Chairman of the Board of Directors at Cerecor, Inc. and is a Member of the Board of Directors at InDex Pharmaceuticals AB and Uppsala University. Earlier in his career he held the position of Professor in Organic Chemistry at Uppsala University where he also received his Ph.D. in 1981.
Helena Danielson, Prof.
Board member since 2006
Prof. Helena Danielson (1959) is Professor of Biochemistry at Uppsala University since 2002, and co-founded Beactica in 2006. She is a specialist in enzyme-based drug discovery and has profound experience of the commercial drug discovery process through more than 25 years of collaborative research with industrial partners.
Her longstanding work with biosensor technology and the Biacore technology for detailed studies of enzyme-inhibitor interactions has resulted in the development of new biosensor products of wide use in the discovery industry.
Board member since 2017
Mr Erik Walldén (1949) has a record of achievement from over 30 years leadership in the international Life Science industry. He has led the global launching of several new technologies, established and restructured companies, successfully closed private placements and IPOs. He is currently acting as consultant and advisor through his own company Erik Wallden AB.
Erik has been the CEO for the Swedish company Gyros AB (2009–2013). Before that he was the CEO of the Swedish biotech company Affibody Holding AB (2006–2009), Biacore International AB (2004–2006), and before that the CEO of Pyrosequencing AB (1998–2004). Erik has been active in establishing and part of the executive management of companies such as the US based PerSeptive Biosystems Inc., Pharmacia Biosensor AB and Pharmacia Biotech AB. He is the Chairman of the Board of Erik Wallden AB, Directors of Virgin Instruments Inc., and CellSeed AB.
Associate Board member since 2018, full Board member since 2019
Mr Håkan Wickholm (1959) has held the roles of CEO and CBO for Lytix Biopharma (2014–2018) and Business Development Director at Pledpharma AB (2013–2014). Before that he worked in various leadership positions at AstraZeneca, including Regional Business Development Director for AstraZeneca CEEMEA (Russia, Central and Eastern Europe & Middle East and Africa) (2009–2012), Vice President of Mature Brands & Local Products at AstraZeneca Sweden/Nordics (2003–2009), General Manager for AstraZeneca Gulf (United Arab Emirates, Oman, Bahrain, Qatar and Kuwait) (2000–2003) as well as various commercial roles in Astra/AstraZeneca (1988–1999).
Håkan has a Postgraduate Diploma in Business Management from Warwick Business School and a B.Sc. in Business Administration and Economics - International Business from Uppsala University.
Maarten de Château
Board member since 2019
Dr Maarten de Château (1963) is currently CEO of Sixera Pharma and Buzzard Pharmaceuticals. He serves as chairman of the Board of Atrogi, and on the Boards of Cavis Technologies and Gesynta Pharma. Maarten was Co-founder and CEO of Cormorant Pharmaceuticals – a company that developed a therapeutic antibody approach in immuno-oncology that was acquired by Bristol-Myers Squibb in 2016. Prior to that, Maarten held the position of Medical Director at Swedish Orphan Biovitrum; he has also worked in clinical development at Sanofi and as an investment bank financial analyst for five years. Maarten holds a PhD and an MD from the University of Lund, Sweden.